ClinicalTrials.gov
ClinicalTrials.gov Menu

Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01826279
Recruitment Status : Unknown
Verified May 2013 by University of Aarhus.
Recruitment status was:  Active, not recruiting
First Posted : April 8, 2013
Last Update Posted : January 30, 2014
Sponsor:
Collaborator:
The Ministry of Science, Technology and Innovation, Denmark
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:

The purpose of this study is to investigate potential metabolic effects of resveratrol in morbidly obese women undergoing gastric bypass surgery.

The investigators hypothesize that resveratrol will:

  • Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion
  • Decrease hepatic and adipose tissue VLDL-TG uptake
  • Increase insulin sensitivity

The investigators will look at changes in:

  • Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry)
  • VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous abdominal adipose tissue, visceral adipose tissue and liver tissue)
  • Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)
  • Regulation of liver fat handling
  • Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)

Condition or disease Intervention/treatment Phase
Obesity Dietary Supplement: Resveratrol Other: Placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Short-term Investigation of Resveratrol on Lipid Turnover in Morbidly Obese Women Undergoing Gastric Bypass Surgery. Effects on Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism and Liver VLDL-triglyceride Uptake.
Study Start Date : May 2013
Estimated Primary Completion Date : August 2014
Estimated Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Resveratrol

Arm Intervention/treatment
Experimental: Resveratrol
Resveratrol 500mg 3 times daily for 1 month
Dietary Supplement: Resveratrol
500mg 3 times daily for 1 month

Placebo Comparator: Placebo
Placebo 1 tablet 3 times daily for 1 month
Other: Placebo
1 placebo tablet 3 times daily for 1 month




Primary Outcome Measures :
  1. Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance [ Time Frame: 1 month ]
    - changes from baseline after treatment with either resveratrol or placebo

  2. Hepatic and adipose VLDL-TG uptake [ Time Frame: 1 month ]
    - changes in VLDL-TG uptake in resveratrol group and placebo group


Secondary Outcome Measures :
  1. Basal and insulin stimulated free fatty acid (FFA) and glucose turnover [ Time Frame: 1 month ]
    - changes from baseline after treatment with either resveratrol or placebo

  2. VLDL-TG oxidation [ Time Frame: 1 month ]
    - changes from baseline after treatment with either resveratrol or placebo

  3. Regulation of liver fat handling [ Time Frame: 1 month ]
    - changes in regulation of liver fat handling in resveratrol group and placebo group



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female
  • 25-60 years
  • Obesity (BMI > 35 kg/m2)
  • Have at least one element of the metabolic syndrome either hypertension and/or hypercholesterolemia (high triglyceride, low HDL-cholesterol)
  • Undergoing gastric bypass surgery
  • Written informed consent

Exclusion Criteria:

  • Any other relevant disease (e.g. diabetes, thyroid or parathyroid disease, heart, kidney or liver disease)
  • May have arthrosis or depression
  • Any present or previous malignancy
  • History of smoking
  • Alcohol dependency (more than 14 units of alcohol per week)
  • Participation in studies with radioactive isotope within the last six months
  • Hemoglobin under the normal range regarding to sex (under 7.3 mmol/l for women)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01826279


Locations
Denmark
Department of Endocrinology and Internal Medicine
Aarhus C, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
The Ministry of Science, Technology and Innovation, Denmark
Investigators
Study Chair: Søren Nielsen, MD, associate professor, DMSc Department of Endocrinology and Internal Medicine

Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01826279     History of Changes
Other Study ID Numbers: M-20110172B
First Posted: April 8, 2013    Key Record Dates
Last Update Posted: January 30, 2014
Last Verified: May 2013

Keywords provided by University of Aarhus:
Obesity
Gastric bypass surgery
Resveratrol
Insulin sensitivity
Lipid turnover
VLDL-triglyceride uptake
Liver

Additional relevant MeSH terms:
Resveratrol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents